Major health insurers have begun the year with encouraging first-quarter results, boosting investor confidence despite ongoing challenges with elevated medical costs. Companies such as UnitedHealth, Elevance, Cigna, and Humana have surpassed analyst expectations for the quarter, with several even raising their financial outlooks for the full year. These positive outcomes were partly anticipated due to seasonal factors, including a less severe flu season and weather patterns that historically tend to suppress medical expenses, according to Barclays analyst Andrew Mok. He further noted that insurers have bolstered their reserves for future claims, a move that provides a financial cushion and supports their forward-looking guidance.
However, a significant caveat remains, as highlighted by Baird analyst Michael Ha. The data available for medical costs in the first quarter is considered incomplete because of a typical lag in claims processing. Expenses related to hospital stays and medical procedures can take one to two months to be fully processed and reimbursed. Consequently, by the end of the first quarter, companies may only have "real hard claims data" from January, leading analysts like Ha to advise investors to "take the first quarter with a grain of salt."
This situation positions the second quarter as the critical period for assessing the true financial health of the sector. As the delayed claims are processed, insurers and investors will gain a more accurate understanding of whether medical costs are aligning with expectations, if the pricing of insurance plans is appropriate, and how these factors will influence earnings for the remainder of the year. "The second quarter is the real underwriting hurdle to pay attention to as you get more claims data that crystallizes your performance for the year in a bigger way," Ha explained. He added that successfully navigating this hurdle could lead to positive earnings implications for 2026.
Beneath the surface of these quarterly beats, the improved performance reflects strategic actions taken by insurers to manage costs after two years of considerable financial pressure. Ha attributes the stronger start to the year partly to "conservative pricing" strategies implemented for key plans, particularly Medicare Advantage. These privately managed Medicare plans have been a significant driver of escalating medical costs for many insurers, as seniors tend to utilize more medical services, especially in the post-pandemic environment.
In response to these pressures, companies have made strategic decisions such as exiting less profitable market segments and reducing membership. They have also adjusted pricing and benefits to better reflect the rising costs of medical care. An example of this strategy is UnitedHealth's announcement in October that it would discontinue its Medicare Advantage plans in 109 U.S. counties starting in 2026, affecting approximately 180,000 members who needed to secure alternative insurance coverage.
"Heading into this year, companies came in with a lot of inherent pricing cushion," Ha stated, indicating that these cost-management efforts are now manifesting in key financial metrics. The medical loss ratio (MLR), which measures medical costs as a percentage of premiums, has come in lower than anticipated for several insurers in the first quarter, signaling improved cost control.
Barclays' Mok pointed out that the first-quarter results were bolstered by strength across all major business segments. In the commercial insurance market, higher premium rates helped to offset increasing medical expenses, while a reduction in benefit offerings contributed to improved performance in the Medicare segment. Mok also highlighted that enhanced cost controls and stabilizing medical costs played a role in the "surprisingly solid results" observed in the Medicaid sector.
He described the Medicaid performance as an "encouraging sign," particularly noteworthy given the current environment where states are tightening eligibility requirements and Medicaid enrollment is declining. Despite these positive developments, the industry is not yet entirely out of the woods, with the second quarter presenting a crucial test for sustained improvement.
The central question is whether the cost-control measures and pricing adjustments will prove effective as more comprehensive claims data becomes available in the second quarter. Due to the inherent delays in medical claims processing, insurers typically rely on estimates when reporting first-quarter financial outcomes. The influx of a larger volume of medical claims during the second quarter will provide a more definitive picture of underlying cost trends.
"Seeing how those claims develop into the second quarter will really help you understand whether you've priced your plans correctly," Mok emphasized. He noted that the second quarter is particularly significant for Humana, which anticipates a 25% growth in Medicare Advantage membership for 2026 while maintaining stable benefits. This strategy bears resemblance to CVS Health's approach in the second quarter of 2024, when it also expanded Medicare Advantage membership with consistent benefits.
However, CVS Health later experienced a significant shortfall in meeting its medical loss ratio targets due to higher-than-expected costs. While not a direct parallel, Ha suggested that a recurrence of such disappointing results poses a potential concern for Humana's upcoming second-quarter performance. The Affordable Care Act (ACA) marketplace also remains a closely watched area for insurers like Centene, Molina, and Elevance during the second quarter.
A key data point for the ACA marketplace is the Wakely analysis, typically released in late June. This analysis helps determine if insurers' revenue projections align with the actual health risk profiles of their enrolled members. Even minor fluctuations in enrollment numbers or the overall health status of members can result in substantial gains or losses in earnings.
Investors will be closely monitoring medical loss ratios and any adjustments to full-year financial outlooks as second-quarter results are released. While insurers are currently benefiting from a favorable reporting environment, the coming months will be pivotal in determining whether this positive momentum can be sustained against the backdrop of evolving medical costs and claims data.
